Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
AstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline
A Peek Into The Markets: U.S. Stock Futures Edge Higher; Crude Oil Drops
Why You (And Another Company) Should Buy Gilead - Dividend Sensei (Seeking Alpha)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

Sep 2016PiperJaffrayInitiates Coverage onOverweight
Sep 2016Exane BNP ParibasDowngradesOutperformNeutral
Sep 2016JefferiesUpgradesHoldBuy

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!